New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
11:38 EDTGALT, CYTK, ATHNOptions with increasing implied volatility: CYTK GALT ATHN
News For CYTK;GALT;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
15:27 EDTATHNathenahealth volatility at low end of historic range
athenahealth March weekly call option implied volatility is at 34, April is at 32, May is at 35, June is at 32; compared to its 26-week average of 38 according to Track Data, suggesting decreasing price movement.
13:15 EDTATHNathenahealth management to meet with Stephens
Subscribe for More Information
07:38 EDTCYTKCytokinetics publishes results from Tirasemtiv Phase II trial
Subscribe for More Information
07:12 EDTATHNAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 23, 2015
10:01 EDTATHNathenahealth management to meet with SunTrust
Subscribe for More Information
March 19, 2015
06:15 EDTATHNathenahealth coverage transferred with an Outperform at RW Baird
Subscribe for More Information
March 18, 2015
17:14 EDTGALTGalectin submitted request for SPA with clinical protocol for GR-MD-02 trial
"I am pleased with our many accomplishments during 2014 as we continue to advance programs with GR-MD-02 for the treatment of nonalcoholic steatohepatitis, NASH, with advanced fibrosis. We completed a successful Phase 1 clinical trial and announced final data in January 2015 that were supportive of our plans to begin a Phase 2 program with GR-MD-02 in advanced fatty liver disease, or NASH with fibrosis and cirrhosis," said Peter G. Traber, M.D., president, CEO and chief medical officer of Galectin Therapeutics. "As announced last month, we submitted the Phase 2 clinical trial protocol to the U.S. Food and Drug Administration, FDA, to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis, the primary endpoint being to determine the change in the hepatic venous pressure gradient, HVPG, as compared with placebo. The FDA has indicated that HVPG may serve as a surrogate primary endpoint for NASH cirrhosis. We submitted a request for a Special Protocol Assessment with the clinical protocol for this trial. Additionally, we are planning to conduct a separate, shorter Phase 2 trial in NASH patients with advanced fibrosis. We expect to begin enrolling patients in both trials during the second quarter of 2015."
17:08 EDTGALTGalectin Therapeutics reports FY14 EPS (78c), consensus (77c)
As of December 31, the company had $29.1M of non-restricted cash and cash equivalents available to fund future operations. In January and February of 2015, the company received $4.1M in net proceeds from the issuance of common shares through its At-the-Market stock issuance program. The company believes that cash on hand of $29.7M as of March 13, is sufficient to fund its operations and research and development activities through September 30, 2016.
March 16, 2015
17:13 EDTGALTGalectin Therapeutics files form to delay 10-K
Galectin Therapeutics is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the period ended December 31. Because the company was previously a smaller reporting company, this is the first time the company must obtain an audit of its internal control over financial reporting. As a result, additional time is needed for the company to provide its independent auditors with information necessary to complete the audit of the company’s internal control over financial reporting. The company anticipates that its Form 10-K will be filed within the prescribed extension period in accordance with Rule 12b-25(b).
March 13, 2015
07:38 EDTCYTKCytokinetics completes enrollment in COSMIC-HF
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use